Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
531 studies found for:    Open Studies | "Melanoma"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Melanoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Prospective Melanoma Database
Condition: Melanoma
Intervention: Other: clinical biological data collection on melanoma
2 Not yet recruiting LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: LY3022855;   Drug: Vemurafenib;   Drug: Cobimetinib
3 Recruiting Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)
Condition: Melanoma
4 Recruiting A Clinical Trial of Patients With Melanoma
Condition: Melanoma
Interventions: Drug: Digoxin Combination;   Drug: Dabrafenib;   Drug: Trametinib
5 Recruiting A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Metformin
6 Recruiting Study Assessing Two Models of Hypofractionated Protontherapy on Large Choroidal Melanomas
Condition: Melanoma
Intervention: Radiation: Protontherapy
7 Recruiting A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Condition: Melanoma
Interventions: Drug: pembrolizumab + epacadostat;   Drug: pembrolizumab + placebo
8 Recruiting In Vivo Real-time Detection of Circulating Melanoma Cells
Condition: Melanoma
9 Recruiting Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Peginterferon alfa-2b
10 Recruiting BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: BGB324+pembrolizumab;   Drug: BGB324+dabrafenib and trametinib;   Drug: pembrolizumab;   Drug: dabrafenib and trametinib
11 Recruiting Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients
Condition: Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Drug: Metformin
12 Not yet recruiting SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients
Conditions: Melanoma;   Metastatic Melanoma
Interventions: Radiation: SAbR;   Drug: Ipilimumab;   Drug: Nivolumab
13 Recruiting A Tolerability and Pharmacokinetics Study of SHR6390 in Advanced Melanoma Patients
Condition: Melanoma
Intervention: Drug: SHR6390
14 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
15 Not yet recruiting Tracing Dissemination of Melanoma Cells in Healthy Tissues
Condition: Melanoma
Intervention: Procedure: Melanoma and peritumoral skin excision
16 Recruiting Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
Condition: Melanoma
Intervention: Drug: regorafenib
17 Recruiting Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma
Condition: Malignant Melanoma
18 Recruiting A Clinical Trial of Adoptive Transfer With Autologous NKT Cells in Metastatic Melanoma Patients
Condition: Melanoma
Intervention: Biological: NKT cells
19 Recruiting PLX3397 KIT in Acral aNd mucOsal Melanoma
Condition: Malignant Melanoma
Intervention: Drug: PLX3397
20 Not yet recruiting Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Pembrolizumab;   Drug: Dabrafenib;   Drug: Trametinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.